These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
852 related articles for article (PubMed ID: 32071277)
41. HBVcircle: A novel tool to investigate hepatitis B virus covalently closed circular DNA. Yan Z; Zeng J; Yu Y; Xiang K; Hu H; Zhou X; Gu L; Wang L; Zhao J; Young JAT; Gao L J Hepatol; 2017 Jun; 66(6):1149-1157. PubMed ID: 28213165 [TBL] [Abstract][Full Text] [Related]
42. Virological Basis for the Cure of Chronic Hepatitis B. Hu J; Cheng J; Tang L; Hu Z; Luo Y; Li Y; Zhou T; Chang J; Guo JT ACS Infect Dis; 2019 May; 5(5):659-674. PubMed ID: 29893548 [TBL] [Abstract][Full Text] [Related]
43. T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR. Qu B; Ni Y; Lempp FA; Vondran FWR; Urban S J Virol; 2018 Dec; 92(23):. PubMed ID: 30232183 [TBL] [Abstract][Full Text] [Related]
44. A Novel Mouse Model Harboring Hepatitis B Virus Covalently Closed Circular DNA. Xu Z; Zhao L; Zhong Y; Zhu C; Zhao K; Teng Y; Cheng X; Chen Q; Xia Y Cell Mol Gastroenterol Hepatol; 2022; 13(4):1001-1017. PubMed ID: 34896285 [TBL] [Abstract][Full Text] [Related]
45. New Insights on Molecular Mechanism of Hepatitis B Virus Covalently Closed Circular DNA Formation. Marchetti AL; Guo H Cells; 2020 Nov; 9(11):. PubMed ID: 33172220 [TBL] [Abstract][Full Text] [Related]
47. Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA. Zhuang AQ; Chen Y; Chen SM; Liu WC; Li Y; Zhang WJ; Wu YH Viruses; 2023 Nov; 15(12):. PubMed ID: 38140556 [TBL] [Abstract][Full Text] [Related]
48. Characterization of the Termini of Cytoplasmic Hepatitis B Virus Deproteinated Relaxed Circular DNA. Cai D; Yan R; Xu JZ; Zhang H; Shen S; Mitra B; Marchetti A; Kim ES; Guo H J Virol; 2020 Dec; 95(1):. PubMed ID: 33055252 [TBL] [Abstract][Full Text] [Related]
49. Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation. Wei ZQ; Zhang YH; Ke CZ; Chen HX; Ren P; He YL; Hu P; Ma DQ; Luo J; Meng ZJ World J Gastroenterol; 2017 Sep; 23(34):6252-6260. PubMed ID: 28974891 [TBL] [Abstract][Full Text] [Related]
50. Establishment of Cre-mediated HBV recombinant cccDNA (rcccDNA) cell line for cccDNA biology and antiviral screening assays. Wu M; Li J; Yue L; Bai L; Li Y; Chen J; Zhang X; Yuan Z Antiviral Res; 2018 Apr; 152():45-52. PubMed ID: 29432776 [TBL] [Abstract][Full Text] [Related]
51. A novel method to precisely quantify hepatitis B virus covalently closed circular (ccc)DNA formation and maintenance. Tu T; Zehnder B; Qu B; Ni Y; Main N; Allweiss L; Dandri M; Shackel N; George J; Urban S Antiviral Res; 2020 Sep; 181():104865. PubMed ID: 32726641 [TBL] [Abstract][Full Text] [Related]
52. Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice. Raney AK; Eggers CM; Kline EF; Guidotti LG; Pontoglio M; Yaniv M; McLachlan A J Virol; 2001 Mar; 75(6):2900-11. PubMed ID: 11222715 [TBL] [Abstract][Full Text] [Related]
53. Revisiting Hepatitis B Virus: Challenges of Curative Therapies. Hu J; Protzer U; Siddiqui A J Virol; 2019 Oct; 93(20):. PubMed ID: 31375584 [TBL] [Abstract][Full Text] [Related]
54. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus. Kostyushev D; Brezgin S; Kostyusheva A; Zarifyan D; Goptar I; Chulanov V Cell Mol Life Sci; 2019 May; 76(9):1779-1794. PubMed ID: 30673820 [TBL] [Abstract][Full Text] [Related]
55. Mechanism of Hepatitis B Virus cccDNA Formation. Wei L; Ploss A Viruses; 2021 Jul; 13(8):. PubMed ID: 34452329 [TBL] [Abstract][Full Text] [Related]
56. Regulation of multiple stages of hepadnavirus replication by the carboxyl-terminal domain of viral core protein in trans. Liu K; Ludgate L; Yuan Z; Hu J J Virol; 2015 Mar; 89(5):2918-30. PubMed ID: 25540387 [TBL] [Abstract][Full Text] [Related]
57. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. Guo H; Jiang D; Zhou T; Cuconati A; Block TM; Guo JT J Virol; 2007 Nov; 81(22):12472-84. PubMed ID: 17804499 [TBL] [Abstract][Full Text] [Related]
58. SLF2 Interacts with the SMC5/6 Complex to Direct Hepatitis B Virus Episomal DNA to Promyelocytic Leukemia Bodies for Transcriptional Repression. Yao Q; Peng B; Li C; Li X; Chen M; Zhou Z; Tang D; He J; Wu Y; Sun Y; Li W J Virol; 2023 Jul; 97(7):e0032823. PubMed ID: 37338350 [TBL] [Abstract][Full Text] [Related]
59. Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B. Goh ZY; Ren EC; Ko HL World J Gastroenterol; 2021 Apr; 27(14):1369-1391. PubMed ID: 33911462 [TBL] [Abstract][Full Text] [Related]
60. PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation. Zhang W; Chen J; Wu M; Zhang X; Zhang M; Yue L; Li Y; Liu J; Li B; Shen F; Wang Y; Bai L; Protzer U; Levrero M; Yuan Z Hepatology; 2017 Aug; 66(2):398-415. PubMed ID: 28236308 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]